DAWN earnings: a negative outcome, -5.7%

On November 8, 2021, Day One Biopharmaceuticals, Inc. reached its earnings. The result was a negative outcome, and the stock moved -5.7% in the window around the event. It had already run +19.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.